AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03753529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure release
Description: First, using a pincer grasp moved throughout the fibers of the pterygoid, masseter, digastric and temporalis muscles to palpate the muscle aiming to locate a trigger point . A common location is detected according to Simon and Travell book. Once located on the trigger point, apply an IC by gradually applying pressure to the trigger point with your thumb. Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points were treated. Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
Study NCT03753529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: Stretching and transcutaneous electrical nerve stimulation
Study NCT01352858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TolDC
Description: Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
Study NCT01352858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arthroscopy & saline irrigation alone
Study NCT02340975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 + tremelimumab
Description: MEDI4736 will be administered by IV infusion in combination with tremelimumab.
Study NCT02340975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 will be administered by IV infusion.
Study NCT02340975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab will be administered by IV infusion.
Study NCT02340975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736+tremelimumab
Description: MEDI4736 will be administered by IV infusion in combination with tremelimumab.
Study NCT02321800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: 2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
Study NCT02321800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/cilastatin
Description: 1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
Study NCT03012165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Drops (0.5%)
Description: ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
Study NCT03012165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-102 Ophthalmic Drops (0.1%)
Description: ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
Study NCT03012165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of ADX-102 Ophthalmic Drops
Description: Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.
Study NCT00720538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
Study NCT00720538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules
Study NCT00064116 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Rituximab 375 mg/m² i.v. day 1
Study NCT00064116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP regimen
Description: Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
Study NCT01746745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-LY2940680
Description: Administered as solution by mouth
Study NCT03535610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine Embolization
Description: Uterine Embolization with PVA Microspheres
Study NCT01103648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Tablets of simvastatin 20 mg administered once a day for 12 weeks
Study NCT01103648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Tablets of ezetimibe 10 mg administered once a day for 12 weeks
Study NCT01103648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Simvastatin plus Ezetimibe
Description: Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).~Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).~This Combination represents the experimental period of the present study.
Study NCT04089384 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
Study NCT04089384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy Group
Description: Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
Study NCT04089384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment).
Study NCT00911053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
Study NCT00911053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Sleep Schedule
Description: Subjects will maintain a regular sleep schedule of their choosing.
Study NCT00911053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light
Description: Subjects will be exposed to light.
Study NCT01028144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.
Study NCT01028144 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Program
Description: A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
Study NCT00696722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo + atazanavir
Description: Placebo treatment first, atazanavir treatment second~4 day treatment
Study NCT00696722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir + placebo
Description: Atazanavir treatment first, placebo treatment second~4 day treatment
Study NCT02723214 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain biopsy
Description: Brain biopsy using either the frame-based stereotactic technique, or a frameless fiducial-less brain biopsy method using an optical based navigation system and a mini frame apparatus - trajectory guide.
Study NCT00704574 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: No extra intervention, only normal clinical practise for treatment of type 1 diabetes
Study NCT00478426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT03447067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Low speed motor with surgiacl round burs and surgical fissure for removal a covering bone with decapitation and guttering formation
Study NCT03447067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBCT
Description: For measuring the bone removeal
Study NCT03447067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBCT
Description: for identifed the nerve
Study NCT01229410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 µg Brimonidine Tartrate Implant
Description: 400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
Study NCT01229410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 µg Brimonidine Tartrate Implant
Description: 200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
Study NCT02929381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovative colonoscopy (Olympus CF-HQ190L, NBI + Dual Focus)
Description: NBI and Dual Focus options will be used to classify lesions according to Kudo and NICE classifications.
Study NCT00390559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine transdermal system
Description: 21 mg nicotine transdermal system
Study NCT02929381 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colonoscopy (Olympus CF-H180DL)
Description: Conventional colonoscopy performed without innovative techniques used in experimental arm.
Study NCT04432376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: miconazole 2% oil
Description: Drug treatment of otomycosis for 14 days
Study NCT04432376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: miconazole 2% oil
Description: Drug treatment of otomycosis for 14 days
Study NCT04255108 — intervention group
Intervention type: DEVICE
Intervention: Cova Patch
Description: CoVa Patch will measure quasi-continuously, approximately every 5 minutes for a period between 6 to 48 hours
Study NCT03362008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zeropix
Description: administration of Zeropix
Study NCT04432376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle oil
Description: Placebo treatment of otomycosis for 14 days
Study NCT03336476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy
Description: Patients will be intubated with the video laryngoscope
Study NCT03336476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: Patients will be intubated with the direct laryngoscope
Study NCT00726492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous short wave diathermy (CSWD)
Description: CSWD applied twice a week for 4 weeks
Study NCT00726492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: Hydrotherapy (exercise in water) attended twice a week for 4 weeks
Study NCT01921699 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: taking blood samples from healthy people
Study NCT03552900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 7cups Mobile App
Description: Participants who receive the 7 Cups mobile app will get access to direct online social support by messaging with a listener, participating in group chats as well as evidence-based information and exercises to promote their mental health.
Study NCT03552900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bliss
Description: Participants who receive the Bliss app will get access to an app that that provides access to important community, health, wellness, academic, and support resources.
Study NCT00470977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab injection (0.5 mg)
Description: ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.
Study NCT00390559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal system
Description: Placebo nicotine patch
Study NCT00390559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine containing cigarette
Description: Nicotine containing cigarette
Study NCT02233491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active lifestyle intervention
Description: Active intervention will comprise reviews by a renal dietician, with cognitive behaviour therapy, to provide additional support for lifestyle intervention.
Study NCT02233491 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No additional support other than lifestyle advice by clinician
Study NCT02050828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778
Study NCT03362008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Champix®
Description: administration of Champix®
Study NCT02050828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT02050828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Study NCT02050828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00582166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab Tiuxetan (Zevalin) + Rituximab
Description: Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
Study NCT03849196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG-Asc
Description: PEG-Asc powder
Study NCT02050828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham
Study NCT04600453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day. The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM combined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
Study NCT03056183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Care Transitions (DCT)
Description: DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
Study NCT04101370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg
Description: Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
Study NCT04101370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tracleer 125Mg Tablet
Description: Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
Study NCT00663689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150mg qd until disease progression or unacceptable toxicity.
Study NCT00982748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pranayama (Yoga Breathing) Techniques
Description: 1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
Study NCT00982748 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pranayama (Yoga Breathing) Techniques
Description: 1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
Study NCT03871465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone SASD injection
Description: 2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
Study NCT03871465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
Study NCT03871465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone injections & Physiotherapy
Description: 2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
Study NCT00763607 — intervention group
Intervention type: GENETIC
Intervention: Protein expression by immunohistochemistry and immunofluorescence
Description: Protein expression by immunohistochemistry and immunofluorescence
Study NCT04129190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Oral Intake of Glucose
Study NCT00632515 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
Study NCT04046601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: impedance
Description: After endoscopic resection of early esophageal cancer, the tissue will be measured by an impedance probe between 10Hz-1000000Hz, 20mV. 8 gold electrodes have been integrated to the probe. The impedance will be measured in different ways between the elctrodes. There will be 10 measurements in total for each specimen.
Study NCT00998036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg
Study NCT00998036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
Study NCT00390559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo cigarette
Description: Non nicotine containing cigarette
Study NCT00998036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg
Study NCT01787045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early and Active Physical Therapy
Description: Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.~Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc.
Study NCT00642850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120, 200 or 360 micrograms iv monthly (starting dose)
Study NCT01900249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 0.2%
Description: R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
Study NCT01900249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 0.5%
Description: R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
Study NCT01900249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
Study NCT01091649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: Low dose ABT-450 / ritonavir see Arm Description for more information
Study NCT01091649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: ritonavir see Arm Description for more information